Immune system

Xencor to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, May 26, 2020

A replay will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days.

Key Points: 
  • A replay will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days.
  • Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases.
  • Currently, 17 candidates engineered with Xencor's XmAb technology are in clinical development internally and with partners.
  • Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action.

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, May 26, 2020

A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

Key Points: 
  • A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
  • CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.
  • CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
  • To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

New Patent Issued to Trianni: Antibody Discovery Platform Optimized for Man's Best Friend -- the Dog

Retrieved on: 
Tuesday, May 26, 2020

Such mice enable the facile discovery of dog antibodies for therapy of disease in dogs.

Key Points: 
  • Such mice enable the facile discovery of dog antibodies for therapy of disease in dogs.
  • The "dog mouse" enables a more streamlined approach to discover antibody therapeutic solutions faster for canines.
  • "The issued patent describes the Trianni technology of introducing the complete dog antibody repertoire into transgenic mice that respond to immunization similar to wild type mice."
  • Trianni currently offers a leading antibody discovery platform with the full human antibody repertoire -- the Trianni Mouse.

Principia Announces Data Presentations of Rilzabrutinib in Patients with Immune Thrombocytopenia (ITP) at Two Upcoming Virtual Medical Meetings

Retrieved on: 
Tuesday, May 26, 2020

Following the presentations, the slides and poster will be available on the Principia website.

Key Points: 
  • Following the presentations, the slides and poster will be available on the Principia website.
  • Unmet needs in relapsed or refractory ITP are to improve remission rates and durability by targeting underlying disease mechanisms.
  • Rilzabrutinib is an oral, small molecule, reversible covalent inhibitor of Brutons tyrosine kinase (BTK) that modulates immune-mediated processes in ITP.
  • Principia is a late-stage biopharmaceutical company dedicated to bringing transformative therapies to patients with significant unmet medical needs in immune-mediated diseases.

Competing in the 2020 Global Enteric Disease Testing Market: Supplier Shares, Segment Forecasts for 10 Assays, Growth Opportunities for Suppliers - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 26, 2020

The report provides test volume and sales forecasts by country and market segment, including:

Key Points: 
  • The report provides test volume and sales forecasts by country and market segment, including:
    In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of enteric disease diagnostic products, by test and country.
  • Examines market applications of Molecular Diagnostics, Monoclonal Antibodies, Immunoassays, IT and other emerging technologies;
    Reviews features and operating characteristics of major analyzers used for enteric disease testing;
    Profiles key suppliers and potential market entrants developing innovative, technologies and products; and

Equillium to Present at Jefferies Virtual Healthcare Conference

Retrieved on: 
Thursday, May 21, 2020

Replays will be available for 30 days following each webcast.

Key Points: 
  • Replays will be available for 30 days following each webcast.
  • Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need.
  • Equilliums initial product candidate, itolizumab (EQ001), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway.
  • This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases.

OncoSec to Present Two Late-Breaking Pre-Clinical Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II

Retrieved on: 
Thursday, May 21, 2020

The data were selected for two late-breaking poster presentations at the American Association for Cancer (AACR) Virtual Annual Meeting II being held June 22-24, 2020.

Key Points: 
  • The data were selected for two late-breaking poster presentations at the American Association for Cancer (AACR) Virtual Annual Meeting II being held June 22-24, 2020.
  • The following posters will be presented during the session titled, Late-Breaking Research: Immunology 2, on June 22, 2020 from 9:00 a.m. 6:00 p.m. EDT:
    Full abstracts are available online at www.aacr.org .
  • OncoSec Medical Incorporated (the "Company," "OncoSec," "we" or "our") is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer.
  • OncoSec's lead immunotherapy investigational product candidate TAVO (tavokinogene telseplasmid) enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions.

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the Digital EAACI Annual Congress 2020

Retrieved on: 
Thursday, May 21, 2020

The following virtual oral abstract presentations will be available starting on June 6, 2020.

Key Points: 
  • The following virtual oral abstract presentations will be available starting on June 6, 2020.
  • Allakos is a late-stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases.
  • Antolimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils.
  • Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs.

Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development for its EMT Inhibitor, AB-16B5

Retrieved on: 
Thursday, May 21, 2020

We are extremely pleased to have achieved this important milestone in the development of AB-16B5 and to continue to advance the clinical development of this promising antibody commented Yves Cornellier, President and CEO of Alethia.

Key Points: 
  • We are extremely pleased to have achieved this important milestone in the development of AB-16B5 and to continue to advance the clinical development of this promising antibody commented Yves Cornellier, President and CEO of Alethia.
  • EMT is a central enabler for solid tumor progression because it triggers metastatic invasion, resistance to several classes of anti-cancer drugs and contributes to immune evasion.
  • There is also increasing evidence that EMT contributes to resistance to immune checkpoint inhibitors.
  • Tumor-associated secreted clusterin is induced early in the EMT cascade and its inhibition with AB-16B5 stops and reverts EMT in animal models.

Medterra CBD Announces New Immune Boost Drops

Retrieved on: 
Wednesday, May 20, 2020

IRVINE, Calif., May 20, 2020 /PRNewswire/ --The leading CBD brand Medterra is thrilled to announce the launch of its new Immune Boost Drops .

Key Points: 
  • IRVINE, Calif., May 20, 2020 /PRNewswire/ --The leading CBD brand Medterra is thrilled to announce the launch of its new Immune Boost Drops .
  • "Consumers are recognizing that your immune system performs much better if you are proactive rather than waiting until they are sick," said Medterra CEO and Co-Founder Jay Hartenbach.
  • "To help, we have accelerated development of our Immune Boosting Blend that supports your immune response, while also helping fight immune system killers like stress and lack of sleep."
  • Immune Boost Blend is composed of several immune boosting ingredients like Elderberry, Echinacea, Ginger Root and more to promote ultimate immune health.